ESH ALL 2021 | Evolving therapy of Ph+ and Ph-like ALL
Stephen Hunger, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, comments on the evolution of the treatment landscape for Philadelphia chromosome-positive (Ph+) and Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL). In an elderly population with Ph+ ALL, where toxicity is a concern, the use of tyrosine kinase inhibitors (TKIs) plus steroids and blinatumomab shows encouraging results. Ultimately, it is critical to understand how it translates to young, healthier adults and children. In the Ph-like ALL space, Dr Hunger highlights the early data suggesting that these patients respond to TKIs. However, in the future is essential to establish whether that is a fact and, indeed, patient outcomes improve with the addition of the appropriate TKI to their therapy. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Dr Hunger has received honoraria from Amgen and Servier, consulting fees from Novartis and owns common stock in Amgen.
